Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis.

Kang JL, Wang XX, Nie ML, Huang XH

Gynecologic and obstetric investigation17 Nov 2009Cited by 26 (Europe PMC)

PMID19923847DOI10.1159/000258683PepBankPUB-19923847

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialEfficacy outcome
In women with adenomyosis and endometriosis, hormone profiles were similar with extended-interval and conventional triptorelin dosing.
In plain wordsIn women with adenomyosis and endometriosis, hormone profiles were similar with extended-interval and conventional triptorelin dosing.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeHormone profile between regimens
Study
n = 70
Comparator
Conventional triptorelin dosing
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg (extended-interval regimen) · intramuscular (extended-interval regimen) · 4 doses every 6 weeks (extended); 6 doses every 4 weeks (conventional)As given in this study (human).
Source sentences
Summary
The hormone profile of the experimental group was similar to that of the control group (p > 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Seventy women suffering from adenomyosis and endometriosis were randomly divided into 2 groups: extended-interval dosing (experimental group) and conventional dosing (control group).
Summary · context
Patients in the experimental group received a 4-dose regimen (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses).
Summary · context
The patients in the control group received a conventional regimen (1 injection every 4 weeks for a total of 6 doses).
Report a problemFND-1992384707

Studies that did not test the peptide alone6

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with adenomyosis and endometriosis, both extended and conventional triptorelin regimens had complete dysmenorrhea relief after 6 months.
In plain wordsIn women with adenomyosis and endometriosis, both triptorelin dosing regimens had complete menstrual pain relief after 6 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseDysmenorrhea relief with both regimens
Study
n = 70
Outcome group
Pain · Reproductive and sexual health
Measurements
Dysmenorrhea relief
100%
both regimens
Source sentences
Summary
The reliving rate of dysmenorrhea was 100% in patients treated with both the new regimen and the convention regimen after 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventy women suffering from adenomyosis and endometriosis were randomly divided into 2 groups: extended-interval dosing (experimental group) and conventional dosing (control group).
Summary · context
Patients in the experimental group received a 4-dose regimen (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses).
Summary · context
The patients in the control group received a conventional regimen (1 injection every 4 weeks for a total of 6 doses).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1992384701
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with adenomyosis and endometriosis, LH levels decreased significantly with both triptorelin dosing regimens.
In plain wordsIn women with adenomyosis and endometriosis, LH levels decreased significantly with both triptorelin dosing regimens.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseLH levels with both regimens
Study
n = 70
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
And the levels of LH, FSH and E(2) were decreased significantly (p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Seventy women suffering from adenomyosis and endometriosis were randomly divided into 2 groups: extended-interval dosing (experimental group) and conventional dosing (control group).
Summary · context
Patients in the experimental group received a 4-dose regimen (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses).
Summary · context
The patients in the control group received a conventional regimen (1 injection every 4 weeks for a total of 6 doses).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1992384704
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with adenomyosis and endometriosis, FSH levels decreased significantly with both triptorelin dosing regimens.
In plain wordsIn women with adenomyosis and endometriosis, FSH levels decreased significantly with both triptorelin dosing regimens.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFSH levels with both regimens
Study
n = 70
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
And the levels of LH, FSH and E(2) were decreased significantly (p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Seventy women suffering from adenomyosis and endometriosis were randomly divided into 2 groups: extended-interval dosing (experimental group) and conventional dosing (control group).
Summary · context
Patients in the experimental group received a 4-dose regimen (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses).
Summary · context
The patients in the control group received a conventional regimen (1 injection every 4 weeks for a total of 6 doses).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1992384705
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with adenomyosis and endometriosis, estradiol decreased significantly to postmenopausal levels with both triptorelin dosing regimens.
In plain wordsIn women with adenomyosis and endometriosis, estradiol decreased to postmenopausal levels with both triptorelin dosing regimens.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseEstradiol levels with both regimens
Study
n = 70
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
And the levels of LH, FSH and E(2) were decreased significantly (p < 0.001). The E(2 )levels were reduced to the postmenopausal level.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventy women suffering from adenomyosis and endometriosis were randomly divided into 2 groups: extended-interval dosing (experimental group) and conventional dosing (control group).
Summary · context
Patients in the experimental group received a 4-dose regimen (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses).
Summary · context
The patients in the control group received a conventional regimen (1 injection every 4 weeks for a total of 6 doses).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1992384706
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with adenomyosis and endometriosis, uterine volume decreased 37.6% with extended-interval triptorelin dosing.
In plain wordsIn women with adenomyosis and endometriosis, womb volume decreased 37.6% with extended-interval triptorelin dosing.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseUterine volume with extended dosing
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Uterine volume reduction
37.6%
extended-interval regimen
Source sentences
Summary
The uterine volume was reduced 37.6% and 39.2%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventy women suffering from adenomyosis and endometriosis were randomly divided into 2 groups: extended-interval dosing (experimental group) and conventional dosing (control group).
Summary · context
Patients in the experimental group received a 4-dose regimen (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses).
Summary · context
The patients in the control group received a conventional regimen (1 injection every 4 weeks for a total of 6 doses).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1992384702
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with adenomyosis and endometriosis, uterine volume decreased 39.2% with conventional triptorelin dosing.
In plain wordsIn women with adenomyosis and endometriosis, womb volume decreased 39.2% with conventional triptorelin dosing.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseUterine volume with conventional dosing
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Uterine volume reduction
39.2%
conventional regimen
Source sentences
Summary
The uterine volume was reduced 37.6% and 39.2%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventy women suffering from adenomyosis and endometriosis were randomly divided into 2 groups: extended-interval dosing (experimental group) and conventional dosing (control group).
Summary · context
Patients in the experimental group received a 4-dose regimen (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses).
Summary · context
The patients in the control group received a conventional regimen (1 injection every 4 weeks for a total of 6 doses).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1992384703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.